Global Substance Abuse Treatment
Global Substance Abuse Treatment

Substance Abuse Treatment Comprehensive Study by Type (Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Drug Abuse Treatment, Other Treatment), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels), End User (Hospitals, Homecare, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Substance Abuse Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 249 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Substance Abuse Treatment Market Overview:
Substance Abuse Treatment market is expected to grow in the future due to the rise in the drug awareness campaigns and associated prevention programs and adoption of newer formulations and novel dosage forms. Substance abuse is the repeated harmful use of any substance, including drugs and alcohol. The substances may be legal, prescription drugs or banned substances as well some that arenít even classified as drugs. Technological advancement in the diagnostics industry is boosting the growth of the market.

Growth Drivers
  • Increasing Number of Drug Awareness Campaigns and Prevention Programs
  • High Number of Addicted Population

Market Trends
  • Technological Advancement in the Diagnostics Industry

Roadblocks
  • Reluctance of Individuals for Accessing Treatment and Discontinuation of the Behavioral Therapies

Opportunities
  • High Usage of Tobacco across the Developing and Developed Nations
  • Growing Healthcare Infrastructure in the Developing Economies
  • Availability of Cost Effective Treatment Option

Challenges
  • Poor Treatment Compliance in Some Countries


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Allergan plc (United States), Sanofi S.A (France), GSK (United Kingdom), Pfizer Inc. (United States), Alkermes (Ireland), Mylan N.V. (United States), Cipla Limited (India), Purdue Pharma L.P. (United States), Reckitt Benckiser Group plc (United Kingdom) and Teva Pharmaceutical (Israel). Analyst at AMA Research see United States Players to retain maximum share of Global Substance Abuse Treatment market by 2026. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Substance Abuse Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Substance Abuse Treatment market.

In Oct 2019, The Trump administration has unveiled a website aimed at helping millions of Americans with substance abuse issues learn about and locate treatment options.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Substance Abuse Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Substance Abuse Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceutical Companies, Pharmacy Chains/Drug Stores, Drug Suppliers/Traders, Drug Exporters/Importers, Investors, Regulatory and Government Bodies, Upstream Vendors, Downstream Vendors and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Alcohol Addiction Treatment
  • Tobacco/Nicotine Addiction Treatment
  • Drug Abuse Treatment
  • Other Treatment
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Drug Awareness Campaigns and Prevention Programs
      • 3.2.2. High Number of Addicted Population
    • 3.3. Market Challenges
      • 3.3.1. Poor Treatment Compliance in Some Countries
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement in the Diagnostics Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Substance Abuse Treatment, by Type, Distribution Channel, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Substance Abuse Treatment (Value)
      • 5.2.1. Global Substance Abuse Treatment by: Type (Value)
        • 5.2.1.1. Alcohol Addiction Treatment
        • 5.2.1.2. Tobacco/Nicotine Addiction Treatment
        • 5.2.1.3. Drug Abuse Treatment
        • 5.2.1.4. Other Treatment
      • 5.2.2. Global Substance Abuse Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Other Distribution Channels
      • 5.2.3. Global Substance Abuse Treatment by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Homecare
        • 5.2.3.3. Specialty Clinics
        • 5.2.3.4. Others
      • 5.2.4. Global Substance Abuse Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Substance Abuse Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan plc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi S.A (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GSK (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Alkermes (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Purdue Pharma L.P. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Reckitt Benckiser Group plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva Pharmaceutical (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Substance Abuse Treatment Sale, by Type, Distribution Channel, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Substance Abuse Treatment (Value)
      • 7.2.1. Global Substance Abuse Treatment by: Type (Value)
        • 7.2.1.1. Alcohol Addiction Treatment
        • 7.2.1.2. Tobacco/Nicotine Addiction Treatment
        • 7.2.1.3. Drug Abuse Treatment
        • 7.2.1.4. Other Treatment
      • 7.2.2. Global Substance Abuse Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Other Distribution Channels
      • 7.2.3. Global Substance Abuse Treatment by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Homecare
        • 7.2.3.3. Specialty Clinics
        • 7.2.3.4. Others
      • 7.2.4. Global Substance Abuse Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Substance Abuse Treatment: by Type(USD Million)
  • Table 2. Substance Abuse Treatment Alcohol Addiction Treatment , by Region USD Million (2015-2020)
  • Table 3. Substance Abuse Treatment Tobacco/Nicotine Addiction Treatment , by Region USD Million (2015-2020)
  • Table 4. Substance Abuse Treatment Drug Abuse Treatment , by Region USD Million (2015-2020)
  • Table 5. Substance Abuse Treatment Other Treatment , by Region USD Million (2015-2020)
  • Table 6. Substance Abuse Treatment: by Distribution Channel(USD Million)
  • Table 7. Substance Abuse Treatment Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Substance Abuse Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Substance Abuse Treatment Other Distribution Channels , by Region USD Million (2015-2020)
  • Table 10. Substance Abuse Treatment: by End User(USD Million)
  • Table 11. Substance Abuse Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 12. Substance Abuse Treatment Homecare , by Region USD Million (2015-2020)
  • Table 13. Substance Abuse Treatment Specialty Clinics , by Region USD Million (2015-2020)
  • Table 14. Substance Abuse Treatment Others , by Region USD Million (2015-2020)
  • Table 15. South America Substance Abuse Treatment, by Country USD Million (2015-2020)
  • Table 16. South America Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 17. South America Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 18. South America Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 19. Brazil Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 20. Brazil Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 22. Argentina Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 23. Argentina Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 24. Argentina Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 25. Rest of South America Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 27. Rest of South America Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 28. Asia Pacific Substance Abuse Treatment, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 31. Asia Pacific Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 32. China Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 33. China Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 34. China Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 35. Japan Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 36. Japan Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 37. Japan Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 38. India Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 39. India Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 40. India Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 41. South Korea Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 42. South Korea Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 43. South Korea Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 44. Taiwan Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 45. Taiwan Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 46. Taiwan Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 47. Australia Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 48. Australia Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 49. Australia Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 53. Europe Substance Abuse Treatment, by Country USD Million (2015-2020)
  • Table 54. Europe Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 55. Europe Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 56. Europe Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 57. Germany Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 58. Germany Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 59. Germany Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 60. France Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 61. France Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 62. France Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 63. Italy Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 64. Italy Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 65. Italy Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 66. United Kingdom Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 67. United Kingdom Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 68. United Kingdom Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 69. Netherlands Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 70. Netherlands Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 71. Netherlands Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 72. Rest of Europe Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 73. Rest of Europe Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 74. Rest of Europe Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 75. MEA Substance Abuse Treatment, by Country USD Million (2015-2020)
  • Table 76. MEA Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 77. MEA Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 78. MEA Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 79. Middle East Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 80. Middle East Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 81. Middle East Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 82. Africa Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 83. Africa Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 84. Africa Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 85. North America Substance Abuse Treatment, by Country USD Million (2015-2020)
  • Table 86. North America Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 87. North America Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 88. North America Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 89. United States Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 90. United States Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 91. United States Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 92. Canada Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 93. Canada Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 94. Canada Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 95. Mexico Substance Abuse Treatment, by Type USD Million (2015-2020)
  • Table 96. Mexico Substance Abuse Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 97. Mexico Substance Abuse Treatment, by End User USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Substance Abuse Treatment: by Type(USD Million)
  • Table 109. Substance Abuse Treatment Alcohol Addiction Treatment , by Region USD Million (2021-2026)
  • Table 110. Substance Abuse Treatment Tobacco/Nicotine Addiction Treatment , by Region USD Million (2021-2026)
  • Table 111. Substance Abuse Treatment Drug Abuse Treatment , by Region USD Million (2021-2026)
  • Table 112. Substance Abuse Treatment Other Treatment , by Region USD Million (2021-2026)
  • Table 113. Substance Abuse Treatment: by Distribution Channel(USD Million)
  • Table 114. Substance Abuse Treatment Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 115. Substance Abuse Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 116. Substance Abuse Treatment Other Distribution Channels , by Region USD Million (2021-2026)
  • Table 117. Substance Abuse Treatment: by End User(USD Million)
  • Table 118. Substance Abuse Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 119. Substance Abuse Treatment Homecare , by Region USD Million (2021-2026)
  • Table 120. Substance Abuse Treatment Specialty Clinics , by Region USD Million (2021-2026)
  • Table 121. Substance Abuse Treatment Others , by Region USD Million (2021-2026)
  • Table 122. South America Substance Abuse Treatment, by Country USD Million (2021-2026)
  • Table 123. South America Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 124. South America Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 125. South America Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 126. Brazil Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 127. Brazil Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 128. Brazil Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 129. Argentina Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 130. Argentina Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 131. Argentina Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 132. Rest of South America Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 133. Rest of South America Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 134. Rest of South America Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 135. Asia Pacific Substance Abuse Treatment, by Country USD Million (2021-2026)
  • Table 136. Asia Pacific Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 137. Asia Pacific Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 138. Asia Pacific Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 139. China Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 140. China Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 141. China Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 142. Japan Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 143. Japan Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 144. Japan Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 145. India Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 146. India Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 147. India Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 148. South Korea Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 149. South Korea Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 150. South Korea Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 151. Taiwan Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 152. Taiwan Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 153. Taiwan Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 154. Australia Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 155. Australia Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 156. Australia Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 160. Europe Substance Abuse Treatment, by Country USD Million (2021-2026)
  • Table 161. Europe Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 162. Europe Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 163. Europe Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 164. Germany Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 165. Germany Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 166. Germany Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 167. France Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 168. France Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 169. France Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 170. Italy Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 171. Italy Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 172. Italy Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 173. United Kingdom Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 174. United Kingdom Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 175. United Kingdom Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 176. Netherlands Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 177. Netherlands Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 178. Netherlands Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 179. Rest of Europe Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 180. Rest of Europe Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 181. Rest of Europe Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 182. MEA Substance Abuse Treatment, by Country USD Million (2021-2026)
  • Table 183. MEA Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 184. MEA Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 185. MEA Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 186. Middle East Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 187. Middle East Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 188. Middle East Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 189. Africa Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 190. Africa Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 191. Africa Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 192. North America Substance Abuse Treatment, by Country USD Million (2021-2026)
  • Table 193. North America Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 194. North America Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 195. North America Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 196. United States Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 197. United States Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 198. United States Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 199. Canada Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 200. Canada Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 201. Canada Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 202. Mexico Substance Abuse Treatment, by Type USD Million (2021-2026)
  • Table 203. Mexico Substance Abuse Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 204. Mexico Substance Abuse Treatment, by End User USD Million (2021-2026)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Substance Abuse Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Substance Abuse Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Substance Abuse Treatment: by End User USD Million (2015-2020)
  • Figure 7. South America Substance Abuse Treatment Share (%), by Country
  • Figure 8. Asia Pacific Substance Abuse Treatment Share (%), by Country
  • Figure 9. Europe Substance Abuse Treatment Share (%), by Country
  • Figure 10. MEA Substance Abuse Treatment Share (%), by Country
  • Figure 11. North America Substance Abuse Treatment Share (%), by Country
  • Figure 12. Global Substance Abuse Treatment share by Players 2020 (%)
  • Figure 13. Global Substance Abuse Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Substance Abuse Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan plc (United States) Revenue, Net Income and Gross profit
  • Figure 17. Allergan plc (United States) Revenue: by Geography 2020
  • Figure 18. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 19. Sanofi S.A (France) Revenue: by Geography 2020
  • Figure 20. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Alkermes (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Alkermes (Ireland) Revenue: by Geography 2020
  • Figure 26. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 28. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 29. Cipla Limited (India) Revenue: by Geography 2020
  • Figure 30. Purdue Pharma L.P. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Purdue Pharma L.P. (United States) Revenue: by Geography 2020
  • Figure 32. Reckitt Benckiser Group plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Reckitt Benckiser Group plc (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva Pharmaceutical (Israel) Revenue: by Geography 2020
  • Figure 36. Global Substance Abuse Treatment: by Type USD Million (2021-2026)
  • Figure 37. Global Substance Abuse Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 38. Global Substance Abuse Treatment: by End User USD Million (2021-2026)
  • Figure 39. South America Substance Abuse Treatment Share (%), by Country
  • Figure 40. Asia Pacific Substance Abuse Treatment Share (%), by Country
  • Figure 41. Europe Substance Abuse Treatment Share (%), by Country
  • Figure 42. MEA Substance Abuse Treatment Share (%), by Country
  • Figure 43. North America Substance Abuse Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Allergan plc (United States)
  • Sanofi S.A (France)
  • GSK (United Kingdom)
  • Pfizer Inc. (United States)
  • Alkermes (Ireland)
  • Mylan N.V. (United States)
  • Cipla Limited (India)
  • Purdue Pharma L.P. (United States)
  • Reckitt Benckiser Group plc (United Kingdom)
  • Teva Pharmaceutical (Israel)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation